Funding Healthcare Companies at Critical Inflection Point

---

We raise capital for late-stage healthcare companies at the exact moment when founders have proven their breakthrough but can't access the capital needed to commercialize.

These are companies where:

• The technology works and has been validated
• Patents are secured and IP is protected
• The team has delivered on milestones
• Seed funding, grants, and philanthropy have been exhausted
• Clinical trials, regulatory approval, and commercial launch require institutional capital

But founders are scientists and innovators, not salespeople. They speak the language of research, not revenue. They've spent years proving their science works—and now they need someone who can translate that achievement into terms institutional investors understand.

That's where we come in.

We work with only 3-5 companies at a time, ensuring comprehensive attention and rigorous standards during the critical commercialization phase. 

Most breakthrough healthcare innovations follow a predictable funding journey:

Stage 1: Proof of Concept

Self-funding, friends and family, seed capital, SBIR grants, philanthropic donations. Founders validate the science, secure initial patents, and demonstrate feasibility.

Stage 2: Development & Validation

Early-stage investors, additional grants, strategic partnerships. Companies build teams, conduct studies, and prove the technology works.

Then comes the gap.

The science is proven. Patents are secured. The team has delivered. Clinical validation is complete or in progress. The regulatory pathway is clear.

But the company has exhausted grants, seed funding, and early capital. They need  $10-50 million for clinical trials, regulatory approval, and commercial launch.

And traditional investors look the other way.

Why This Gap Exists:

Early-stage venture capital has moved on to newer opportunities. Late-stage institutional investors don't see companies at this stage. They invest in proven commercial entities with revenue.

Founders are brilliant scientists but aren't salespeople. They can't articulate their breakthrough in terms institutional capital understands. They speak research language, not business language.

They've run out of money and can't afford traditional capital raise consultants who require $50,000+ upfront fees.

How We Bridge The Gap:

We work on performance—you don't pay unless we successfully secure funding. We translate scientific achievement into investment opportunity. 

We position regulatory milestones as fundable plans. We present clinical validation as de-risked commercial potential.

We only take on companies we genuinely believe can reach patients—because our success depends on yours.

Every company passes comprehensive due diligence before we represent them:

• Management integrity and capability
• IP ownership and freedom to operate
• Financial viability and capital efficiency
• Clear regulatory pathway
• Ethical standards and patient benefit

If a company doesn't meet these standards, we don't work with them—regardless of the science or potential fees.

We conduct this comprehensive assessment before taking on any company. If they don't meet these standards, we don't move forward—regardless of the science or potential fees. This protects both the companies we represent and the investors we introduce them to. 

For companies that have exhausted their runway...

Pure 10% success fee (5% cash, 5% equity). No retainer required.

This means you don't pay unless we successfully secure funding. We only take on companies we genuinely believe can reach patients—because our success depends on yours.

For companies with available capital...

$10,000 monthly retainer (credited at closing) + 10% success fee (5% cash, 5% equity)

The retainer covers our time conducting due diligence, developing your investor materials, and making introductions. It accumulates as a credit toward the success fee at closing.

Why we take equity:

Taking 50% of our success fee in equity isn't standard in this business. We do it to prove we're committed to your long-term success, not just closing a deal. When you win, we win. When you succeed commercially, we benefit from that success. 

This model protects you from wasted time.

For institutional investors and family offices, this eliminates months of sorting through unqualified deals. 

You only see companies that have:

• Passed rigorous due diligence
• Been properly positioned for institutional capital
• Demonstrated real commercial potential
• Proven their science works

We eliminate months of sorting through unqualified deals. Every company we present has been thoroughly vetted and is ready for institutional investment.